Heartdrug : excellence in cardiovascular trials最新文献_第5页

Heartdrug : excellence in cardiovascular trials Pub Date : 2004-12-01 DOI: 10.1159/000082186

K. Kjeldsen, Jan Bech, Thomas Andersen Schmidt

{"title":"Mentorship in Medical Research","authors":"K. Kjeldsen, Jan Bech, Thomas Andersen Schmidt","doi":"10.1159/000082186","DOIUrl":"https://doi.org/10.1159/000082186","url":null,"abstract":"Mentorship has been recognised as essential for success in medical research. We describe how to make contact with the medical research community and find a mentor. Moreover, we describe how to establish a working relationship with a proficient mentor and provide answers to some of the most important questions that the novice in medical research should always ask himself before committing himself to a supervisor: What is your bid – and what is your mentor’s quid pro quo in the relationship? How do you find a field of research? How do you evaluate a potential mentor? How can you make first contact with a mentor? And what about resources? It is important that the student’s expectations regarding the mentor’s input – and vice versa – are well defined at an early stage. We advocate finding a field of research that genuinely interests you and, most importantly, where you have a proven record of your industriousness. A mentor should be evaluated on the basis of his insight and knowledge as well as the time he can spare for supervision and productivity. PubMed and Science Citation Index checks may give useful information regarding a supervisor’s publication profile; but you should also take into account someone’s reputation as a supervisor. A mentor should provide the resources needed to get started. Try to obtain an appointment with a prospective mentor and go there prepared by having read relevant information. Start contemplating the research plan once both parties decide to give it a go. It will serve as a written agreement between student and mentor.","PeriodicalId":87985,"journal":{"name":"Heartdrug : excellence in cardiovascular trials","volume":"4 1","pages":"168 - 174"},"PeriodicalIF":0.0,"publicationDate":"2004-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000082186","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65255135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Late Complications of Diabetes mellitus in the Republic of Uzbekistan 乌兹别克斯坦共和国糖尿病的晚期并发症

Heartdrug : excellence in cardiovascular trials Pub Date : 2004-12-01 DOI: 10.1159/000082188

S. I. Ismailov, D. Berdykulova, F. Khaidarova

{"title":"Late Complications of Diabetes mellitus in the Republic of Uzbekistan","authors":"S. I. Ismailov, D. Berdykulova, F. Khaidarova","doi":"10.1159/000082188","DOIUrl":"https://doi.org/10.1159/000082188","url":null,"abstract":"Background: Diabetes mellitus (DM) is a major cause of blindness, and cardiovascular risk is the highest in diabetics. More than 40% of all trauma-unrelated lower extremity amputations are performed because of diabetic foot syndrome and lower extremity gangrene; 35–40% of all deaths due to uremia occur in diabetics. Objective: To study the prevalence of late complications of DM in the Republic of Uzbekistan and risk factors contributing to their progression. Methods: 1,000 and 1,141 patients with type 2 DM, resident in urban and rural areas of Uzbekistan, respectively, underwent general clinical examination in which arterial pressure, carbohydrate and lipid metabolism parameters were measured. A special questionnaire was filled out for each patient. Results: The study established a higher prevalence of late complications of DM in urban diabetics as compared with those in rural regions (p < 0.001). The incidence of macroangiopathies of lower extremity vessels, diabetic foot syndrome and myocardial infarction was found to be higher in males than that in females, while the prevalence of ischemic heart disease was registered as higher in females regardless of region. An increase in the incidence of late complications of DM with disease duration was found in residents of both regions (p < 0.001). The prevalence of macroangiopathies, diabetic polyneuropathy and diabetic foot syndrome in the decompensated stage of disease was high among both urban and rural residents. The smokers had a higher prevalence of diabetic retinopathy, macroangiopathies of lower extremity vessels, myocardial infarction and ischemic heart disease regardless of region. Age also contributes to the progression of late complications of DM. Conclusions: The incidence of late complications of DM was higher in urban diabetics than in their rural counterparts in the present study. Sex, age, disease duration, compensation stage and bad habits were found to be risk factors for the progression of late complications of DM.","PeriodicalId":87985,"journal":{"name":"Heartdrug : excellence in cardiovascular trials","volume":"4 1","pages":"177 - 183"},"PeriodicalIF":0.0,"publicationDate":"2004-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000082188","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65255312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Age-Dependent Therapeutic Effects of Once-Daily Molsidomine Used as an Add-On Treatment in Patients with Stable Angina pectoris 每日一次莫西多明作为稳定型心绞痛患者附加治疗的年龄依赖性治疗效果

Heartdrug : excellence in cardiovascular trials Pub Date : 2004-12-01 DOI: 10.1159/000082189

R. Messin, Fabienne Carreer-Bruhwyler, C. Dubois, J. Famaey, J. Géczy

{"title":"Age-Dependent Therapeutic Effects of Once-Daily Molsidomine Used as an Add-On Treatment in Patients with Stable Angina pectoris","authors":"R. Messin, Fabienne Carreer-Bruhwyler, C. Dubois, J. Famaey, J. Géczy","doi":"10.1159/000082189","DOIUrl":"https://doi.org/10.1159/000082189","url":null,"abstract":"Background: A once-daily 16-mg-dose formulation of molsidomine (Coruno® tablets) was recently developed for the chronic treatment of angina pectoris. It required efficacy and safety testing. Objective: The objective of the present study was to compare the efficacy and tolerability of Coruno with that of the currently prescribed twice-daily 8-mg dose of molsidomine (Corvatard® tablets), using them as add-on therapies in patients with stable angina pectoris aged either less or more than 75 years. Methods: 133 patients (including 55 elderly patients of at least 75 years) received molsidomine 8 mg twice daily (M8) for at least 1 month as add-on therapy before enrollment. The study itself consisted of a 1-week period during which patients went on with M8, followed by a 4-week period during which M8 was replaced by molsidomine 16 mg once daily (M16). The frequency of anginal attacks and short-acting nitroderivative consumption for symptomatic relief were measured, and the quality of life was assessed by validated questionnaires. Results: M16 significantly reduced the incidence of anginal attacks in elderly patients compared with M8. The same significant benefit was not observed in younger patients. A nonsignificant decrease in the consumption of nitroderivatives for pain relief was recorded in both age groups. From 3 weeks of treatment, M16 did not induce more drug-related adverse events than M8. It had no significant effect on blood pressure, heart rate or ECG. Conclusions: M16 was as safe and effective as M8 in controlling angina, reducing the frequency of anginal attacks even more in the elderly compared with the younger patient group.","PeriodicalId":87985,"journal":{"name":"Heartdrug : excellence in cardiovascular trials","volume":"4 1","pages":"184 - 189"},"PeriodicalIF":0.0,"publicationDate":"2004-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000082189","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65255422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Author Index Vol. 4, 2004 作者索引第4卷，2004年

Heartdrug : excellence in cardiovascular trials Pub Date : 2004-12-01 DOI: 10.1159/000082989

引用次数: 0

Congress Calendar 国会的日历

Heartdrug : excellence in cardiovascular trials Pub Date : 2004-12-01 DOI: 10.1159/000082988

引用次数: 0

Editors’ Note 编者注

Heartdrug : excellence in cardiovascular trials Pub Date : 2004-12-01 DOI: 10.1159/000082185

D. Atar, Hideo Kusuoka, Victor L. Serebruany, Philip R. Liebson

引用次数: 0

Subject Index Vol. 4, 2004 主题索引第4卷，2004年

Heartdrug : excellence in cardiovascular trials Pub Date : 2004-12-01 DOI: 10.1159/000082990

R. Messin, Fabienne Carreer-Bruhwyler, C. Dubois, J. Famaey, F. Khaidarova, J. Géczy, D. Atar, H. Kusuoka, P. Liebson, V. Serebruany, K. Kjeldsen, Jan Bech, T. Schmidt, Einar Stranden, J. Shoemaker, K. Birkeland, S. I. Ismailov, D. Berdykulova

引用次数: 0

Contents Vol. 4, 2004 目录2004年第4卷

Heartdrug : excellence in cardiovascular trials Pub Date : 2004-12-01 DOI: 10.1159/000082991

R. Messin, Fabienne Carreer-Bruhwyler, C. Dubois, J. Famaey, F. Khaidarova, J. Géczy, D. Atar, H. Kusuoka, P. Liebson, V. Serebruany, K. Kjeldsen, Jan Bech, T. Schmidt, Einar Stranden, J. Shoemaker, K. Birkeland, S. I. Ismailov, D. Berdykulova

引用次数: 0

Peripheral Chemoreceptor Contributions to Cardiovascular Regulation 外周化学受体在心血管调节中的作用

Heartdrug : excellence in cardiovascular trials Pub Date : 2004-12-01 DOI: 10.1159/000082190

J. Shoemaker

{"title":"Peripheral Chemoreceptor Contributions to Cardiovascular Regulation","authors":"J. Shoemaker","doi":"10.1159/000082190","DOIUrl":"https://doi.org/10.1159/000082190","url":null,"abstract":"Oxygen homeostasis at the cellular level depends on acute and appropriate cardiovascular adjustments elicited by neural chemosensitive reflexes. This review addresses the integrated physiology of peripheral chemoreflex control of cardiovascular function with emphasis on the relevance for the intact and conscious human. Peripheral chemoreceptor activation affects sympathoexcitatory and cardiovascular responses that can be modified by the concurrent effects of enhanced ventilation. Additional changes in baroreflex control during chemoreceptor activation must be considered in determining chemoreflex-mediated cardiovascular regulation. Moreover, the autonomic response elicited by the peripheral chemoreflex may enhance the sensitivity of these chemoreceptors, further enhancing or prolonging the neural and cardiovascular consequences of hypoxia. Finally, the recent interest in the role of altered chemoreflex sensitivity and function in cardiovascular pathology is highlighted. The collective information suggests that these interactions may contribute importantly to cardiovascular pathology requiring considerable research into the linkage between cellular and genomic mechanisms that affect the integrated systems response in health and disease.","PeriodicalId":87985,"journal":{"name":"Heartdrug : excellence in cardiovascular trials","volume":"4 1","pages":"190 - 200"},"PeriodicalIF":0.0,"publicationDate":"2004-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000082190","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65255059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Methods for the Evaluation of Vascular Reconstruction 评价血管重建效果的方法

Heartdrug : excellence in cardiovascular trials Pub Date : 2004-12-01 DOI: 10.1159/000082191

E. Stranden

引用次数: 1